Literature DB >> 1909261

Seroepidemiology of hepatitis C virus infection in the Philippines: a preliminary study and comparison with hepatitis B virus infection among blood donors, medical personnel, and patient groups in Davao, Philippines.

M O Arguillas1, E O Domingo, F Tsuda, M Mayumi, H Suzuki.   

Abstract

To determine the seroprevalence of hepatitis C virus in the Philippines and compare it with the seroprevalence of hepatitis B virus infection, HBV and HCV markers in 594 serum samples collected from 392 blood donors, 123 medical and paramedical personnel, and 80 patients (45 liver diseases: 25 acute hepatitis, 9 liver cirrhosis, and 11 hepatocellular carcinoma; 28 hepatitis B carriers, and 7 chronic renal failure patients undergoing dialysis) in Davao, Mindanao Island, Philippines, were examined. HBsAg was determined by RPHA, anti-HBc by HI, anti-HBs by PHA, and HBsAg subtypes, HBeAg, and anti-HBe by EIA. HCV markers determined were anti-HCV (anti-C100-3) by ELISA (Ortho Diagnostic Systems), and anti-HCV core (anti-CP9 and/or anti-CP10) also by ELISA. Results showed that 9 (2.2%) blood donors were anti HCV positive; 69 (15.4%) were anti-HCV core positive Nine (2.2%) were HBsAg carriers; 240 (61.3%) were anti-HBs and/or anti-HBc positive (HBsAg carriers excluded from this group). Two of 123 medical and paramedical staff (1.6%) were anti-HCV positive; 11 (8.1%) were anti-HCV core positive; Eight (6.5%) were HBsAg carriers and 81 (65.8%) anti-HBs and/or anti-HBc positive. Five of 11 (45.4%) hepatocellular carcinoma patients were HBsAg carriers; 2 were anti-HCV core positive. Two of 9 liver cirrhosis patients were anti-HCV positive (1 to anti-HCV and the other to anti-HCV core).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1909261     DOI: 10.1007/bf02779292

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  6 in total

1.  The prevalence of HIV, HBV and HCV among Filipino blood donors and overseas work visa applicants.

Authors:  Yumiko Yanase; Takashi Ohida; Yoshitaka Kaneita; Dorothy May D Agdamag; Prisca Susan A Leaño; Christopher J Gill
Journal:  Bull World Health Organ       Date:  2007-02       Impact factor: 9.408

2.  Hepatitis C Virus Exposure Rate among Health-care Workers in Rural Lower Egypt Governorates.

Authors:  Ashraf Elbahrawy; Ahmed Elwassief; Abdallah Mahmoud Abdallah; Arafat Kasem; Sadek Mostafa; Khaled Makboul; Mohamed Salah Ali; Ahmed Alashker; Ahmed Maher Eliwa; Hossam Shahbah; Mohamed Abdellah Othman; Mohamed Hanafy Morsy; Mohamed Ali Abdelbaseer; Hafez Abdelhafeez
Journal:  J Transl Int Med       Date:  2017-09-30

Review 3.  Hepatitis B virus and hepatitis C virus infection in healthcare workers.

Authors:  Nicola Coppola; Stefania De Pascalis; Lorenzo Onorato; Federica Calò; Caterina Sagnelli; Evangelista Sagnelli
Journal:  World J Hepatol       Date:  2016-02-18

Review 4.  Estimation of Cancer Burden Attributable to Infection in Asia.

Authors:  He Huang; Xiao-Feng Hu; Fang-Hui Zhao; Suzanne M Garland; Neerja Bhatla; You-Lin Qiao
Journal:  J Epidemiol       Date:  2015-09-19       Impact factor: 3.211

5.  Decreasing Hepatitis C Virus Infection in Thailand in the Past Decade: Evidence from the 2014 National Survey.

Authors:  Rujipat Wasitthankasem; Nawarat Posuwan; Preeyaporn Vichaiwattana; Apiradee Theamboonlers; Sirapa Klinfueng; Viboonsak Vuthitanachot; Napha Thanetkongtong; Siriporn Saelao; Monthana Foonoi; Apinya Fakthongyoo; Jamorn Makaroon; Klaita Srisingh; Duangporn Asawarachun; Somchai Owatanapanich; Norra Wutthiratkowit; Kraisorn Tohtubtiang; Pornsak Yoocharoen; Sompong Vongpunsawad; Yong Poovorawan
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

Review 6.  Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations.

Authors:  Dalia Omran; Mohamed Alboraie; Rania A Zayed; Mohamed-Naguib Wifi; Mervat Naguib; Mohamed Eltabbakh; Mohamed Abdellah; Ahmed Fouad Sherief; Sahar Maklad; Heba Hamdy Eldemellawy; Omar Khalid Saad; Doaa Mohamed Khamiss; Mohamed El Kassas
Journal:  World J Gastroenterol       Date:  2018-10-14       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.